Who founded Adrenomed AG?

Adrenomed AG was founded by Gerald Moeller in 2009.

Who are Adrenomed AG's investors?

Adrenomed AG's investors include Brandenburg Kapital, Catalyze Capital, VU Venture Partners.

Where is Adrenomed AG headquartered?

Adrenomed AG is headquartered in Hennigsdorf, DE.

Adrenomed AG

Hennigsdorf, DE · Founded 2009 · 3 known investors

Find your way into Adrenomed AG

240 people in our graph share verified history with the Adrenomed AG team — schools, employers, funds. One of them is your warm intro.

Damien McDevittunlockedknows Richard Jones · together at Akcea Therapeutics (overlapped)

knows the team · via Adrenomed AG

×3knows the team · via Shire

×7knows the team · via GSK

AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.

Biotech Healthtech Medical Devices

Founders & leadership

Adrenomed AG was founded in 2009 by Gerald Moeller.

Gerald MoellerCo-founder and former CEO of AdrenoMed; Supervisory Board member

Richard Jones Chief Executive Officer (CEO)Richard Jones has held CEO positions at small biotechnology companies and senior roles at major pharmaceutical firms, with expertise spanning rare diseases, oncology, hematology, cell and gene therapies, and infectious diseases across drug discovery, development, manufacturing, and commercialization.

David GermonpréChief Financial Officer (CFO)

Investors · 3

Brandenburg Kapitallisted by Brandenburg KapitalPotsdam · $108K – $5.4M

Catalyze Capitallisted by Catalyze CapitalAmsterdam · $1.6M

VU Venture Partnerslisted by VU Venture PartnersSan Francisco · $200K – $1M

How we know: the VCSheet dataset · Not right? Tell us

Frequently asked questions

What does Adrenomed AG do?: AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.
Who founded Adrenomed AG?: Adrenomed AG was founded by Gerald Moeller in 2009.
Who are Adrenomed AG's investors?: Adrenomed AG's investors include Brandenburg Kapital, Catalyze Capital, VU Venture Partners.
Where is Adrenomed AG headquartered?: Adrenomed AG is headquartered in Hennigsdorf, DE.